14 results
Thumbnail

D1.452 - Remission as a therapeutic goal in chronic rhinosinusitis with nasal polyps treated with Dupilumab: a multicenter real-world study

Thumbnail

D1.453 - Pregnancy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): a case report and literature review

Thumbnail

D1.455 - Dupilumab Efficacy in Unified Airways Disease: Pooled Analysis of Patients With Chronic Rhinosinusitis With Nasal Polyps/Allergic Fungal Rhinosinusitis With Coexisting Asthma in Ph3/4 Clinical Trials

Thumbnail

D1.457 - Clinical and immune profile of newborns born to mothers with inflammatory diseases exposed to biological drugs during pregnancy

Thumbnail

D1.460 - Diagnostic Opportunities in Type 2 Inflammations - A Machine-Learning Approach: EAACI Task Force Update

Thumbnail

D1.461 - Dupilumab as a Steroid-Sparing Treatment Option for Pemphigus Vulgaris: A Case Series from a Tertiary Centre

Thumbnail

D1.463 - Real-World Transition from Reference Omalizumab to Biosimilar Omlyclo in Patients with Chronic Urticaria: A Single-Center Descriptive Study

Thumbnail

D1.451 - Adherence and persistence to biological treatments in patients with CRSwNP and comorbid asthma

Thumbnail

D1.456 - Integrated Analysis of Nemolizumab Immunogenicity Indicates No Effect on the Overall Benefit-Risk Profile of Nemolizumab in Patients with Atopic Dermatitis or with Prurigo Nodularis

Thumbnail

- D3.545 - Natural Killer and Dendritic Cells Leverage Synergistic Interactions to Enhance Treatment of Non-Small Cell Lung Cancer

Thumbnail

- D3.544 - Allergic biomarkers and clinical outcomes in lung cancer patients treated with immune checkpoint inhibitors: a pilot study

Thumbnail

- D3.546 - AllergoOncology: Basophil number and subpopulation proportions may offer potential as predictive biomarkers in non-small cell lung cancer

Thumbnail

- D3.547 - Clinical Outcomes and Safety of Drug Desensitization in Chemotherapy-Induced Hypersensitivity

Thumbnail

- D3.548 - Refractory and persistent pruritus in an atopic patient: A red flag for underlying malignancy?